Compelling Relationship of CYP3A Induction to Levels of the Putative Biomarker 4β-Hydroxycholesterol and Changes in Midazolam Exposure

被引：9

作者：

Mangold, James B. ^{[1
]}

Wu, Fan ^{[1
]}

Rebello, Sam ^{[1
]}

机构：

[1] Novartis Inst Biomed Res, Drug Metab & Pharmacokinet, E Hanover, NJ 07936 USA

来源：

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT | 2016年 / 5卷 / 04期

关键词：

ENDOGENOUS BIOMARKERS; CYTOCHROME-P450; 3A; INHIBITION; MARKER; METABOLISM; IMPACT;

D O I：

10.1002/cpdd.265

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：245 / 249

页数：5

共 20 条

[11] Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing [J].

Kacevska, Marina ;

Robertson, Graham R. ;

Clarke, Stephen J. ;

Liddle, Christopher .

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2008, 4 (02) :137-149

[12] Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4β-Hydroxycholesterol [J].

Kanebratt, K. P. ;

Diczfalusy, U. ;

Backstrom, T. ;

Sparve, E. ;

Bredberg, E. ;

Bottiger, Y. ;

Andersson, T. B. ;

Bertilsson, L. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (05) :589-594

[13] Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects [J].

Kasichayanula, Sreeneeranj ;

Boulton, David W. ;

Luo, Wen-Lin ;

Rodrigues, A. David ;

Yang, Zheng ;

Goodenough, Angela ;

Lee, Michelle ;

Jemal, Mohammed ;

LaCreta, Frank .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (05) :1122-1134

[14] Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction, and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir [J].

Kirby, Brian J. ;

Collier, Ann C. ;

Kharasch, Evan D. ;

Whittington, Dale ;

Thummel, Kenneth E. ;

Unadkat, Jashvant D. .

DRUG METABOLISM AND DISPOSITION, 2011, 39 (06) :1070-1078

[15] Model-Based Exposure-Response Analysis of Apixaban to Quantify Bleeding Risk in Special Populations of Subjects Undergoing Orthopedic Surgery [J].

Leil, Ta ;

Frost, C. ;

Wang, X. ;

Pfister, M. ;

LaCreta, F. .

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2014, 3 (09)

[16] Evaluation of Endogenous Metabolic Markers of Hepatic CYP3A Activity Using Metabolic Profiling and Midazolam Clearance [J].

Shin, K-H ;

Choi, M. H. ;

Lim, K. S. ;

Yu, K-S ;

Jang, I-J ;

Cho, J-Y .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (05) :601-609

[17] Inhibition of Human Cytochrome P450 3A4 by Cholesterol [J].

Shinkyo, Raku ;

Guengerich, F. Peter .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (21) :18426-18433

[18] Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation [J].

Suzuki, Yosuke ;

Itoh, Hiroki ;

Sato, Fuminori ;

Kawasaki, Kanako ;

Sato, Yukie ;

Fujioka, Takashi ;

Sato, Yuhki ;

Ohno, Keiko ;

Mimata, Hiromitsu ;

Kishino, Satoshi .

JOURNAL OF LIPID RESEARCH, 2013, 54 (09) :2568-2572

[19] CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease [J].

Woolsey, Sarah J. ;

Mansell, Sara E. ;

Kim, Richard B. ;

Tirona, Rommel G. ;

Beaton, Melanie D. .

DRUG METABOLISM AND DISPOSITION, 2015, 43 (10) :1484-1490

[20] Does the Long Plasma Half-Life of 4β-Hydroxycholesterol Impact Its Utility as a Cytochrome P450 3A (CYP3A) Metric? [J].

Yang, Zheng ;

Rodrigues, A. David .

JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (11) :1330-1338

← 1 2 →